René Bernards (Rene Bernards, R Bernards)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 77

Top Venues

Agendia BV

Universiteit Leiden (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Agendia BV

Netherlands

Chief Scientific Officer :: Research and Development

Universiteit Utrecht

Netherlands

Professor of Molecular Carcinogenesis :: Molecular Cancer Research

The Netherlands Cancer Institute

Netherlands

Senior Scientist :: Molecular Carcinogenesis

Massachusetts General Hospital Cancer Center

United States

Assistant Professor :: Molecular Genetics

Education History

Universiteit Leiden

Netherlands

PHD :: Molecular Biology

Publications

Robin A Jansen, Sara Mainardi, Matheus Henrique Dias, Astrid Bosma, Emma van Dijk, Roland Selig, Wolfgang Albrecht, Stefan A Laufer, Lars Zender, René Bernards
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers. Proceedings of the National Academy of Sciences of the United States of America 121 (9) (2024)
Matheus H Dias, Vladyslava Liudkovska, Jasmine Montenegro Navarro, Lisanne Giebel, Julien Champagne, Chrysa Papagianni, Onno B Bleijerveld, Arno Velds, Reuven Agami, René Bernards, Maciej Ciesla
The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing. EMBO reports 25 (5) (2024)
Mary C Clark, Rongze Olivia Lu, Winson S Ho, Matheus Henrique Dias, René Bernards, Stephen J Forman
A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm. Molecular oncology (2024)
Matheus H Dias, Vladyslava Liudkovska, Jasmine Montenegro Navarro, Lisanne Giebel, Julien Champagne, Chrysa Papagianni, Onno B Bleijerveld, Arno Velds, Reuven Agami, René Bernards, Maciej Ciesla
The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing. EMBO reports 25 (5) (2024)
Matheus Henrique Dias, Anoek Friskes, Siying Wang, João M Fernandes Neto, Frank van Gemert, Soufiane M C Mourragui, Chrysa Papagianni, Hendrik J Kuiken, Sara Mainardi, Daniel Alvarez-Villanueva, Cor Lieftink, Ben Morris, Anna Dekker, Emma van Dijk, Lieke H S Wilms, Marcelo Santos da Silva, Robin A Jansen, Antonio Mulero-Sanchez, Elke Malzer, August Vidal Bel, Cristina Santos, Ramón Salazar, Rosangela A M Wailemann, Thompson E P Torres, Giulia De Conti, Jonne A Raaijmakers, Petur Snaebjornsson, Sheng-Xian Yuan, Wenxin Qin, John S Kovach, Hugo Aguirre Armelin, Hein Te Riele, Alexander van Oudernaarden, Haojie Jin, Roderick L Beijersbergen, Alberto Villanueva, René H Medema, René Bernards
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy. Cancer discovery 14 (7) (2024)
Alaa Embaby, Sanne C F A Huijberts, Liqin Wang, Rodrigo Leite de Oliveira, Hilde Rosing, Bastiaan Nuijen, Joyce Sanders, Ingrid Hofland, Charlaine van Steenis, Roelof J C Kluin, Cor Lieftink, Christopher G Smith, Christian U Blank, Johannes V van Thienen, John B A G Haanen, Neeltje Steeghs, Frans L Opdam, Jos H Beijnen, Alwin D R Huitema, René Bernards, Jan H M Schellens, Sofie Wilgenhof
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Mary C Clark, Rongze Olivia Lu, Winson S Ho, Matheus Henrique Dias, René Bernards, Stephen J Forman
A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm. Molecular oncology (2024)
Robin A Jansen, Sara Mainardi, Matheus Henrique Dias, Astrid Bosma, Emma van Dijk, Roland Selig, Wolfgang Albrecht, Stefan A Laufer, Lars Zender, René Bernards
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers. Proceedings of the National Academy of Sciences of the United States of America 121 (9) (2024)
Matheus H Dias, Vladyslava Liudkovska, Jasmine Montenegro Navarro, Lisanne Giebel, Julien Champagne, Chrysa Papagianni, Onno B Bleijerveld, Arno Velds, Reuven Agami, René Bernards, Maciej Ciesla
The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing. EMBO reports 25 (5) (2024)
Robin A Jansen, Sara Mainardi, Matheus Henrique Dias, Astrid Bosma, Emma van Dijk, Roland Selig, Wolfgang Albrecht, Stefan A Laufer, Lars Zender, René Bernards
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers. Proceedings of the National Academy of Sciences of the United States of America 121 (9) (2024)
Robin A Jansen, Sara Mainardi, Matheus Henrique Dias, Astrid Bosma, Emma van Dijk, Roland Selig, Wolfgang Albrecht, Stefan A Laufer, Lars Zender, René Bernards
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers. Proceedings of the National Academy of Sciences of the United States of America 121 (9) (2024)
Matheus Henrique Dias, Anoek Friskes, Siying Wang, João M Fernandes Neto, Frank van Gemert, Soufiane M C Mourragui, Chrysa Papagianni, Hendrik J Kuiken, Sara Mainardi, Daniel Alvarez-Villanueva, Cor Lieftink, Ben Morris, Anna Dekker, Emma van Dijk, Lieke H S Wilms, Marcelo Santos da Silva, Robin A Jansen, Antonio Mulero-Sanchez, Elke Malzer, August Vidal Bel, Cristina Santos, Ramón Salazar, Rosangela A M Wailemann, Thompson E P Torres, Giulia De Conti, Jonne A Raaijmakers, Petur Snaebjornsson, Sheng-Xian Yuan, Wenxin Qin, John S Kovach, Hugo Aguirre Armelin, Hein Te Riele, Alexander van Oudernaarden, Haojie Jin, Roderick L Beijersbergen, Alberto Villanueva, René H Medema, René Bernards
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy. Cancer discovery 14 (7) (2024)
Alaa Embaby, Sanne C F A Huijberts, Liqin Wang, Rodrigo Leite de Oliveira, Hilde Rosing, Bastiaan Nuijen, Joyce Sanders, Ingrid Hofland, Charlaine van Steenis, Roelof J C Kluin, Cor Lieftink, Christopher G Smith, Christian U Blank, Johannes V van Thienen, John B A G Haanen, Neeltje Steeghs, Frans L Opdam, Jos H Beijnen, Alwin D R Huitema, René Bernards, Jan H M Schellens, Sofie Wilgenhof
A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Matheus H Dias, Vladyslava Liudkovska, Jasmine Montenegro Navarro, Lisanne Giebel, Julien Champagne, Chrysa Papagianni, Onno B Bleijerveld, Arno Velds, Reuven Agami, René Bernards, Maciej Ciesla
The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing. EMBO reports 25 (5) (2024)
Matheus H Dias, Vladyslava Liudkovska, Jasmine Montenegro Navarro, Lisanne Giebel, Julien Champagne, Chrysa Papagianni, Onno B Bleijerveld, Arno Velds, Reuven Agami, René Bernards, Maciej Ciesla
The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing. EMBO reports (2024)
Ian E Krop, Lorenza Mittempergher, Joseph N Paulson, Fabrice Andre, Hervé R Bonnefoi, Sherene Loi, Sibylle Loibl, Richard D Gelber, Carmela Caballero, Rajith Bhaskaran, Christa Dreezen, Andrea R Menicucci, René Bernards, Laura J van 't Veer, Martine J Piccart
Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial. JCO precision oncology 8 (2024)
Matheus Henrique Dias, Anoek Friskes, Siying Wang, João M Fernandes Neto, Frank van Gemert, Soufiane M C Mourragui, Chrysa Papagianni, Hendrik J Kuiken, Sara Mainardi, Daniel Alvarez-Villanueva, Cor Lieftink, Ben Morris, Anna Dekker, Emma van Dijk, Lieke H S Wilms, Marcelo Santos da Silva, Robin A Jansen, Antonio Mulero-Sanchez, Elke Malzer, August Vidal Bel, Cristina Santos, Ramón Salazar, Rosangela A M Wailemann, Thompson E P Torres, Giulia De Conti, Jonne A Raaijmakers, Petur Snaebjornsson, Sheng-Xian Yuan, Wenxin Qin, John S Kovach, Hugo Aguirre Armelin, Hein Te Riele, Alexander van Oudernaarden, Haojie Jin, Roderick L Beijersbergen, Alberto Villanueva, René H Medema, René Bernards
Paradoxical activation of oncogenic signaling as a cancer treatment strategy. Cancer discovery (2024)
Mariangela Russo, Mengnuo Chen, Elisa Mariella, Haoning Peng, Sumaiyah K Rehman, Elena Sancho, Alberto Sogari, Tzen S Toh, Nathalie Q Balaban, Eduard Batlle, René Bernards, Mathew J Garnett, Matthew Hangauer, Eleonora Leucci, Jean-Christophe Marine, Catherine A O'Brien, Yaara Oren, E Elizabeth Patton, Caroline Robert, Susan M Rosenberg, Shensi Shen, Alberto Bardelli
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nature reviews. Cancer (2024)
Matheus H Dias, Vladyslava Liudkovska, Jasmine Montenegro Navarro, Lisanne Giebel, Julien Champagne, Chrysa Papagianni, Onno B Bleijerveld, Arno Velds, Reuven Agami, René Bernards, Maciej Ciesla
The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing. EMBO reports 25 (5) (2024)
Matheus Henrique Dias, Anoek Friskes, Siying Wang, João M Fernandes Neto, Frank van Gemert, Soufiane M C Mourragui, Chrysa Papagianni, Hendrik J Kuiken, Sara Mainardi, Daniel Alvarez-Villanueva, Cor Lieftink, Ben Morris, Anna Dekker, Emma van Dijk, Lieke H S Wilms, Marcelo Santos da Silva, Robin A Jansen, Antonio Mulero-Sanchez, Elke Malzer, August Vidal Bel, Cristina Santos, Ramón Salazar, Rosangela A M Wailemann, Thompson E P Torres, Giulia De Conti, Jonne A Raaijmakers, Petur Snaebjornsson, Sheng-Xian Yuan, Wenxin Qin, John S Kovach, Hugo Aguirre Armelin, Hein Te Riele, Alexander van Oudernaarden, Haojie Jin, Roderick L Beijersbergen, Alberto Villanueva, René H Medema, René Bernards
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy. Cancer discovery 14 (7) (2024)
Robin A Jansen, Sara Mainardi, Matheus Henrique Dias, Astrid Bosma, Emma van Dijk, Roland Selig, Wolfgang Albrecht, Stefan A Laufer, Lars Zender, René Bernards
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers. Proceedings of the National Academy of Sciences of the United States of America 121 (9) (2024)
Haojie Jin, Zhen Sun, René Bernards
LICOB: a powerful organoid platform for drug discovery. Cell research (2023)
René Bernards
More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics. Molecular oncology 17 (3) (2023)
Ana Ruiz-Saenz, Chloe E Atreya, Changjun Wang, Qiang Sun, Courtney A Dreyer, Diede Brunen, Anirudh Prahallad, Denise P Muñoz, Dana J Ramms, Valeria Burghi, Danislav S Spassov, Eleanor Fewings, Y Christina Hwang, Cynthia Cowdrey, Christina Moelders, Cecilia Schwarzer, Denise M Wolf, Byron Hann, Scott R VandenBerg, Kevan M Shokat, Mark M Moasser, René Bernards, Jorge Silvio Gutkind, Laura van 't Veer, Jean-Philippe Coppé
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF V600E colorectal tumors. Nature cancer 4 (2) (2023)
René Bernards
More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics. Molecular oncology 17 (3) (2023)
René Bernards
More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics. Molecular oncology 17 (3) (2023)
Ana Ruiz-Saenz, Chloe E Atreya, Changjun Wang, Qiang Sun, Courtney A Dreyer, Diede Brunen, Anirudh Prahallad, Denise P Muñoz, Dana J Ramms, Valeria Burghi, Danislav S Spassov, Eleanor Fewings, Y Christina Hwang, Cynthia Cowdrey, Christina Moelders, Cecilia Schwarzer, Denise M Wolf, Byron Hann, Scott R VandenBerg, Kevan M Shokat, Mark M Moasser, René Bernards, Jorge Silvio Gutkind, Laura van 't Veer, Jean-Philippe Coppé
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF V600E colorectal tumors. Nature cancer (2023)
René Bernards
More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics. Molecular oncology (2023)
Sara Mainardi, René Bernards
RASON, a new player in cancer's Premier League. Cell research (2023)
Ana Ruiz-Saenz, Chloe E Atreya, Changjun Wang, Qiang Sun, Courtney A Dreyer, Diede Brunen, Anirudh Prahallad, Denise P Muñoz, Dana J Ramms, Valeria Burghi, Danislav S Spassov, Eleanor Fewings, Y Christina Hwang, Cynthia Cowdrey, Christina Moelders, Cecilia Schwarzer, Denise M Wolf, Byron Hann, Scott R VandenBerg, Kevan M Shokat, Mark M Moasser, René Bernards, Jorge Silvio Gutkind, Laura van 't Veer, Jean-Philippe Coppé
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF V600E colorectal tumors. Nature cancer (2023)
René Bernards
More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics. Molecular oncology 17 (3) (2023)
Ana Ruiz-Saenz, Chloe E Atreya, Changjun Wang, Qiang Sun, Courtney A Dreyer, Diede Brunen, Anirudh Prahallad, Denise P Muñoz, Dana J Ramms, Valeria Burghi, Danislav S Spassov, Eleanor Fewings, Y Christina Hwang, Cynthia Cowdrey, Christina Moelders, Cecilia Schwarzer, Denise M Wolf, Byron Hann, Scott R VandenBerg, Kevan M Shokat, Mark M Moasser, René Bernards, Jorge Silvio Gutkind, Laura van 't Veer, Jean-Philippe Coppé
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF V600E colorectal tumors. Nature cancer 4 (2) (2023)
Sara Mainardi, René Bernards
RASON, a new player in cancer's Premier League. Cell research 33 (1) (2023)
Antonio Mulero-Sanchez, Christel F A Ramirez, Aimée du Chatinier, Hui Wang, Sofie J I Koomen, Ji-Ying Song, Marnix H P de Groot, Cor Lieftink, Astrid Bosma, Artur Burylo, Olaf van Tellingen, Roderick L Beijersbergen, Cun Wang, Leila Akkari, René Bernards, Sara Mainardi
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma. Molecular oncology (2023)
Antonio Mulero-Sanchez, Christel Fa Ramirez, Aimée du Chatinier, Hui Wang, Sofie J I Koomen, Ji-Ying Song, Marnix Hp de Groot, Cor Lieftink, Astrid Bosma, Artur Burylo, Olaf van Tellingen, Roderick L Beijersbergen, Cun Wang, Leila Akkari, René Bernards, Sara Mainardi
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma. Molecular oncology (2023)
Ana Ruiz-Saenz, Chloe E Atreya, Changjun Wang, Qiang Sun, Courtney A Dreyer, Diede Brunen, Anirudh Prahallad, Denise P Muñoz, Dana J Ramms, Valeria Burghi, Danislav S Spassov, Eleanor Fewings, Y Christina Hwang, Cynthia Cowdrey, Christina Moelders, Cecilia Schwarzer, Denise M Wolf, Byron Hann, Scott R VandenBerg, Kevan M Shokat, Mark M Moasser, René Bernards, Jorge Silvio Gutkind, Laura van 't Veer, Jean-Philippe Coppé
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF V600E colorectal tumors. Nature cancer 4 (2) (2023)
René Bernards
More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics. Molecular oncology (2023)
Sara Mainardi, René Bernards
RASON, a new player in cancer's Premier League. Cell research 33 (1) (2023)
René Bernards
More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics. Molecular oncology 17 (3) (2023)
Kevin M Ryan, Jane Smith, René Bernards
Molecular Oncology and the EACR: new partners in communicating and supporting cancer research. Molecular oncology 17 (6) (2023)
Sara Mainardi, René Bernards
RASON, a new player in cancer's Premier League. Cell research 33 (1) (2023)
Ana Ruiz-Saenz, Chloe E Atreya, Changjun Wang, Qiang Sun, Courtney A Dreyer, Diede Brunen, Anirudh Prahallad, Denise P Muñoz, Dana J Ramms, Valeria Burghi, Danislav S Spassov, Eleanor Fewings, Y Christina Hwang, Cynthia Cowdrey, Christina Moelders, Cecilia Schwarzer, Denise M Wolf, Byron Hann, Scott R VandenBerg, Kevan M Shokat, Mark M Moasser, René Bernards, Jorge Silvio Gutkind, Laura van 't Veer, Jean-Philippe Coppé
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF V600E colorectal tumors. Nature cancer 4 (2) (2023)
Haojie Jin, Liqin Wang, René Bernards
Rational combinations of targeted cancer therapies: background, advances and challenges. Nature reviews. Drug discovery 22 (3) (2022)
Ziva Pogacar, Kelvin Groot, Fleur Jochems, Matheus Dos Santos Dias, Antonio Mulero-Sanchez, Ben Morris, Mieke Roosen, Leyma Wardak, Giulia De Conti, Arno Velds, Cor Lieftink, Bram Thijssen, Roderick L Beijersbergen, René Bernards, Rodrigo Leite de Oliveira
Genetic and compound screens uncover factors modulating cancer cell response to indisulam. Life science alliance 5 (9) (2022)
Lizelle Correia, Ramiro Magno, Joana M Xavier, Bernardo P de Almeida, Isabel Duarte, Filipa Esteves, Marinella Ghezzo, Matthew D Eldridge, Chong Sun, Astrid Bosma, Lorenza Mittempergher, Ana Marreiros, René Bernards, Carlos Caldas, Suet-Feung Chin, Ana-Teresa Maia
Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant. NPJ breast cancer 8 (1) (2022)
Haojie Jin, Liqin Wang, René Bernards
Rational combinations of targeted cancer therapies: background, advances and challenges. Nature reviews. Drug discovery (2022)
Liqin Wang, Haojie Jin, Fleur Jochems, Siying Wang, Cor Lieftink, Isabel Mora Martinez, Giulia De Conti, Finn Edwards, Rodrigo Leite de Oliveira, Arnout Schepers, Yang-Yang Zhou, Jiaojiao Zheng, Wei Wu, Xingling Zheng, Shengxian Yuan, Jing Ling, Kathy Jastrzebski, Matheus Dos Santos Dias, Ji-Ying Song, Patrick N H Celie, Hideo Yagita, Ming Yao, Wei-Ping Zhou, Roderick L Beijersbergen, Wenxin Qin, René Bernards
cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis. Nature cancer 3 (11) (2022)
Haojie Jin, Liqin Wang, René Bernards
Rational combinations of targeted cancer therapies: background, advances and challenges. Nature reviews. Drug discovery 22 (3) (2022)
Liqin Wang, Lina Lankhorst, René Bernards
Exploiting senescence for the treatment of cancer. Nature reviews. Cancer 22 (6) (2022)
Chen Yang, Hailin Zhang, Linmeng Zhang, Andrew X Zhu, René Bernards, Wenxin Qin, Cun Wang
Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nature reviews. Gastroenterology & hepatology (2022)
Haojie Jin, Liqin Wang, René Bernards
Rational combinations of targeted cancer therapies: background, advances and challenges. Nature reviews. Drug discovery 22 (3) (2022)
Xuhui Ma, Shanshan Wu, Botai Li, Qianqian Zhang, Jianming Zhang, Wenming Liu, He-Xin Yan, René Bernards, Wenxin Qin, Cun Wang
EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma. Cell discovery 8 (1) (2022)
Haojie Jin, Liqin Wang, René Bernards
Rational combinations of targeted cancer therapies: background, advances and challenges. Nature reviews. Drug discovery (2022)
Marta Llaurado Fernandez, E Marielle Hijmans, Annemiek M C Gennissen, Nelson K Y Wong, Shang Li, G Bea A Wisman, Aleksandra Hamilton, Joshua Hoenisch, Amy Dawson, Cheng-Han Lee, Madison Bittner, Hannah Kim, Gabriel E DiMattia, Christianne A R Lok, Cor Lieftink, Roderick L Beijersbergen, Steven de Jong, Mark S Carey, René Bernards, Katrien Berns
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition. Molecular cancer therapeutics 21 (12) (2022)
Barbara Steurer, Roel C Janssens, Marit E Geijer, Fernando Aprile-Garcia, Bart Geverts, Arjan F Theil, Barbara Hummel, Martin E van Royen, Bastiaan Evers, René Bernards, Adriaan B Houtsmuller, Ritwick Sawarkar, Jurgen A Marteijn
DNA damage-induced transcription stress triggers the genome-wide degradation of promoter-bound Pol II. Nature communications 13 (1) (2022)
Cun Wang, Ying Cao, Chen Yang, René Bernards, Wenxin Qin
Exploring liver cancer biology through functional genetic screens. Nature reviews. Gastroenterology & hepatology 18 (10) (2021)
Marit E Geijer, Di Zhou, Kathiresan Selvam, Barbara Steurer, Chirantani Mukherjee, Bastiaan Evers, Simona Cugusi, Marvin van Toorn, Melanie van der Woude, Roel C Janssens, Yannick P Kok, Wenzhi Gong, Anja Raams, Calvin S Y Lo, Joyce H G Lebbink, Bart Geverts, Dalton A Plummer, Karel Bezstarosti, Arjan F Theil, Richard Mitter, Adriaan B Houtsmuller, Wim Vermeulen, Jeroen A A Demmers, Shisheng Li, Marcel A T M van Vugt, Hannes Lans, René Bernards, Jesper Q Svejstrup, Arnab Ray Chaudhuri, John J Wyrick, Jurgen A Marteijn
Elongation factor ELOF1 drives transcription-coupled repair and prevents genome instability. Nature cell biology 23 (6) (2021)
Federica Di Nicolantonio, Pietro Paolo Vitiello, Silvia Marsoni, Salvatore Siena, Josep Tabernero, Livio Trusolino, René Bernards, Alberto Bardelli
Precision oncology in metastatic colorectal cancer - from biology to medicine. Nature reviews. Clinical oncology 18 (8) (2021)
Yuchen Guo, Jun Wang, Bente Benedict, Chen Yang, Frank van Gemert, Xuhui Ma, Dongmei Gao, Hui Wang, Shu Zhang, Cor Lieftink, Roderick L Beijersbergen, Hein Te Riele, Xiaohang Qiao, Qiang Gao, Chong Sun, Wenxin Qin, René Bernards, Cun Wang
Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer. Genome medicine 13 (1) (2021)
Matheus Henrique Dias, René Bernards
Playing cancer at its own game: activating mitogenic signaling as a paradoxical intervention. Molecular oncology 15 (8) (2021)
Giulia De Conti, Matheus Henrique Dias, René Bernards
Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells. Cancers 13 (5) (2021)
Haojie Jin, Yaoping Shi, Yuanyuan Lv, Shengxian Yuan, Christel F A Ramirez, Cor Lieftink, Liqin Wang, Siying Wang, Cun Wang, Matheus Henrique Dias, Fleur Jochems, Yuan Yang, Astrid Bosma, E Marielle Hijmans, Marnix H P de Groot, Serena Vegna, Dan Cui, Yang-Yang Zhou, Jing Ling, Hui Wang, Yuchen Guo, Xingling Zheng, Nikita Isima, Haiqiu Wu, Chong Sun, Roderick L Beijersbergen, Leila Akkari, Wei-Ping Zhou, Bo Zhai, Wenxin Qin, René Bernards
EGFR activation limits the response of liver cancer to lenvatinib. Nature 595 (7869) (2021)
Haojie Jin, Siying Wang, Esther A Zaal, Cun Wang, Haiqiu Wu, Astrid Bosma, Fleur Jochems, Nikita Isima, Guangzhi Jin, Cor Lieftink, Roderick Beijersbergen, Celia R Berkers, Wenxin Qin, René Bernards
A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. eLife 9 (2020)
João M Fernandes Neto, Ernest Nadal, Evert Bosdriesz, Salo N Ooft, Lourdes Farre, Chelsea M McLean, Sjoerd Klarenbeek, Anouk Jurgens, Hannes Hagen, Liqin Wang, Enriqueta Felip, Alex Martinez-Marti, August Vidal, Emile E Voest, Lodewyk F A Wessels, Olaf van Tellingen, Alberto Villanueva, René Bernards
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. Nature communications 11 (1) (2020)
Cun Wang, Hui Wang, Cor Lieftink, Aimee du Chatinier, Dongmei Gao, Guangzhi Jin, Haojie Jin, Roderick L Beijersbergen, Wenxin Qin, René Bernards
CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut 69 (4) (2019)
Jean-Philippe Coppé, Miki Mori, Bo Pan, Christina Yau, Denise M Wolf, Ana Ruiz-Saenz, Diede Brunen, Anirudh Prahallad, Paulien Cornelissen-Steijger, Kristel Kemper, Christian Posch, Changjun Wang, Courtney A Dreyer, Oscar Krijgsman, Pei Rong Evelyn Lee, Zhongzhong Chen, Daniel S Peeper, Mark M Moasser, René Bernards, Laura J van 't Veer
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. Nature cell biology 21 (6) (2019)
Floris H Groenendijk, Tina Treece, Erin Yoder, Paul Baron, Peter Beitsch, William Audeh, Winand N M Dinjens, René Bernards, Pat Whitworth
Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers. NPJ breast cancer 5 (2019)
Cun Wang, Haojie Jin, Dongmei Gao, Liqin Wang, Bastiaan Evers, Zheng Xue, Guangzhi Jin, Cor Lieftink, Roderick L Beijersbergen, Wenxin Qin, René Bernards
A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma. Cell research 28 (6) (2018)
Zheng Xue, Daniel J Vis, Alejandra Bruna, Tonci Sustic, Sake van Wageningen, Ankita Sati Batra, Oscar M Rueda, Evert Bosdriesz, Carlos Caldas, Lodewyk F A Wessels, René Bernards
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell research 28 (7) (2018)
Rodrigo Leite de Oliveira, René Bernards
Anti-cancer therapy: senescence is the new black. The EMBO journal 37 (10) (2018)
Sara Mainardi, Antonio Mulero-Sánchez, Anirudh Prahallad, Giovanni Germano, Astrid Bosma, Paul Krimpenfort, Cor Lieftink, Jeffrey D Steinberg, Niels de Wit, Samuel Gonçalves-Ribeiro, Ernest Nadal, Alberto Bardelli, Alberto Villanueva, René Bernards
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nature medicine 24 (7) (2018)
Katrien Berns, Joseph J Caumanns, E Marielle Hijmans, Annemiek M C Gennissen, Tesa M Severson, Bastiaan Evers, G Bea A Wisman, Gert Jan Meersma, Cor Lieftink, Roderick L Beijersbergen, Hiroaki Itamochi, Ate G J van der Zee, Steven de Jong, René Bernards
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene 37 (33) (2018)
Marcelo Sobral-Leite, Koen K van de Vijver, Magali Michaut, Rianne van der Linden, Gerrit K J Hooijer, Hugo Mark Horlings, Tesa M Severson, Anna Marie Mulligan, Nayana Weerasooriya, Joyce Sanders, Annuska M Glas, Diederik Wehkamp, Lorenza Mittempergher, Kelly Kersten, Ashley Cimino-Mathews, Dennis Peters, Erik Hooijberg, Annegien Broeks, Marc J van de Vijver, René Bernards, Irene L Andrulis, Marleen Kok, Karin E de Visser, Marjanka K Schmidt
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. Oncoimmunology 7 (12) (2018)
Rodrigo Leite de Oliveira, Liqin Wang, René Bernards
With great power comes great vulnerability. Molecular & cellular oncology 5 (6) (2018)
Subarna Sinha, Daniel Thomas, Steven Chan, Yang Gao, Diede Brunen, Damoun Torabi, Andreas Reinisch, David Hernandez, Andy Chan, Erinn B Rankin, René Bernards, Ravindra Majeti, David L Dill
Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature communications 8 (2017)
Bastiaan Evers, Katarzyna Jastrzebski, Jeroen P M Heijmans, Wipawadee Grernrum, Roderick L Beijersbergen, René Bernards
CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nature biotechnology 34 (6) (2016)
J Johnson, B Thijssen, U McDermott, M Garnett, L F A Wessels, René Bernards
Targeting the RB-E2F pathway in breast cancer. Oncogene 35 (37) (2016)
Justin Guinney, Rodrigo Dienstmann, Xin Wang, Aurélien de Reyniès, Andreas Schlicker, Charlotte Soneson, Laetitia Marisa, Paul Roepman, Gift Nyamundanda, Paolo Angelino, Brian M Bot, Jeffrey S Morris, Iris M Simon, Sarah Gerster, Evelyn Fessler, Felipe De Sousa E Melo, Edoardo Missiaglia, Hena Ramay, David Barras, Krisztian Homicsko, Dipen Maru, Ganiraju C Manyam, Bradley M Broom, Valerie Boige, Beatriz Perez-Villamil, Ted Laderas, Ramon Salazar, Joe W Gray, Douglas Hanahan, Josep Tabernero, René Bernards, Stephen H Friend, Pierre Laurent-Puig, Jan Paul Medema, Anguraj Sadanandam, Lodewyk Wessels, Mauro Delorenzi, Scott Kopetz, Louis Vermeulen, Sabine Tejpar
The consensus molecular subtypes of colorectal cancer. Nature medicine 21 (11) (2015)
A Prahallad, René Bernards
Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene 35 (9) (2015)

René Bernards.css-eqlu8i{font-size:small;padding-left:4px;} (Rene Bernards, R Bernards)

Publication Activity (10 Years)

Top Topics

Top Venues

René Bernards (Rene Bernards, R Bernards)